Share Price and Basic Stock Data
Last Updated: January 7, 2026, 10:12 am
| PEG Ratio | 2.67 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Poly Medicure Ltd operates in the medical equipment and accessories sector, reporting a price of ₹1,788 and a market capitalization of ₹18,127 Cr. The company has shown robust revenue growth, with sales increasing from ₹1,115 Cr in FY 2023 to ₹1,375 Cr in FY 2024, and projected to reach ₹1,669 Cr in FY 2025. The quarterly sales figures also reflect this upward trajectory, rising from ₹275 Cr in September 2022 to ₹337 Cr in September 2023, with a further increase to ₹420 Cr anticipated by September 2024. This consistent growth can be attributed to the increasing demand for medical devices, driven by an aging population and a greater focus on healthcare quality. The company’s operating profit margin (OPM) stood at 26%, indicating effective cost management alongside revenue growth. As the healthcare sector continues to expand, Poly Medicure is well-positioned to capitalize on emerging opportunities.
Profitability and Efficiency Metrics
Poly Medicure has demonstrated strong profitability metrics, as evidenced by a return on equity (ROE) of 15.8% and a return on capital employed (ROCE) of 20.1%. The company reported a net profit of ₹362 Cr for the trailing twelve months (TTM), with an earnings per share (EPS) of ₹34.13. The operating profit for FY 2025 is expected to reach ₹455 Cr, which corresponds to an OPM of 27%. The interest coverage ratio (ICR) of 45.18x highlights the company’s ability to comfortably meet its interest obligations, reflecting financial stability. However, the cash conversion cycle (CCC) of 239 days indicates a potential area for improvement, as longer cycles can tie up working capital. Despite this, the overall profitability and efficiency metrics position Poly Medicure favorably compared to industry norms, suggesting effective operations and solid financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Poly Medicure reflects considerable strength, with total assets amounting to ₹3,587 Cr and total liabilities at ₹3,192 Cr as of March 2025. The company maintains low borrowings of ₹240 Cr, resulting in a total debt-to-equity ratio of 0.06, which is favorable compared to typical industry standards. The reserves have grown significantly from ₹1,194 Cr in FY 2023 to ₹2,868 Cr in September 2025, indicating robust retained earnings and financial resilience. The current ratio stands at a healthy 5.18, suggesting excellent liquidity. Additionally, the price-to-book value (P/BV) ratio of 8.21x indicates a premium valuation compared to its book value, which can be interpreted as market confidence in the company’s future growth prospects. Overall, these financial ratios underscore Poly Medicure’s solid financial position and ability to sustain growth.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Poly Medicure indicates a stable ownership structure, with promoters holding 62.42% of the shares as of September 2025. This significant promoter stake reflects strong management commitment and confidence in the company’s future. Foreign institutional investors (FIIs) hold 9.77%, while domestic institutional investors (DIIs) account for 13.53%. The public shareholding stands at 14.28%, with the number of shareholders increasing to 64,400, suggesting growing retail interest in the company. The gradual decline in FIIs from 16.33% in December 2022 to the current level may raise questions about foreign confidence, but the stable promoter and increasing public holdings provide a counterbalance. This diverse investor base, combined with robust financial performance, indicates a solid foundation for investor confidence moving forward.
Outlook, Risks, and Final Insight
Looking ahead, Poly Medicure is poised for continued growth driven by rising healthcare demands and expanding product offerings. However, risks such as fluctuations in raw material costs and regulatory changes in the medical device industry could impact profitability. Additionally, the company’s high cash conversion cycle may lead to liquidity challenges if not managed effectively. Despite these risks, the strong balance sheet, solid profitability metrics, and increasing shareholder base provide a favorable outlook. Investors should consider these factors when assessing the company’s future potential. Should Poly Medicure successfully address its operational efficiencies and maintain its growth trajectory, it stands to enhance its market position significantly in the medical equipment sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 65.3 Cr. | 52.1 | 120/46.0 | 14.8 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 35.7 Cr. | 97.8 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 23.1 Cr. | 16.0 | 25.5/14.0 | 11.2 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 17,869 Cr. | 1,763 | 2,938/1,683 | 49.4 | 288 | 0.20 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 69.3 Cr. | 38.0 | 86.9/37.5 | 20.8 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 17,869.00 Cr | 393.38 | 24.05 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 275 | 285 | 307 | 321 | 337 | 340 | 378 | 385 | 420 | 424 | 441 | 403 | 444 |
| Expenses | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 |
| Operating Profit | 65 | 71 | 83 | 87 | 84 | 90 | 96 | 104 | 115 | 115 | 119 | 106 | 115 |
| OPM % | 24% | 25% | 27% | 27% | 25% | 27% | 26% | 27% | 27% | 27% | 27% | 26% | 26% |
| Other Income | 9 | 15 | 9 | 14 | 15 | 17 | 15 | 17 | 27 | 24 | 27 | 43 | 35 |
| Interest | 0 | 5 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 |
| Depreciation | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 | 23 | 25 |
| Profit before tax | 59 | 67 | 75 | 83 | 81 | 88 | 92 | 98 | 118 | 113 | 123 | 123 | 122 |
| Tax % | 27% | 25% | 22% | 24% | 23% | 26% | 26% | 25% | 26% | 25% | 25% | 24% | 25% |
| Net Profit | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 |
| EPS in Rs | 4.54 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 8.63 | 8.41 | 9.06 | 9.19 | 9.06 |
Last Updated: December 29, 2025, 3:09 pm
Below is a detailed analysis of the quarterly data for Poly Medicure Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 444.00 Cr.. The value appears strong and on an upward trend. It has increased from 403.00 Cr. (Jun 2025) to 444.00 Cr., marking an increase of 41.00 Cr..
- For Expenses, as of Sep 2025, the value is 329.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 298.00 Cr. (Jun 2025) to 329.00 Cr., marking an increase of 31.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 115.00 Cr.. The value appears strong and on an upward trend. It has increased from 106.00 Cr. (Jun 2025) to 115.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Other Income, as of Sep 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 43.00 Cr. (Jun 2025) to 35.00 Cr., marking a decrease of 8.00 Cr..
- For Interest, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 3.00 Cr..
- For Depreciation, as of Sep 2025, the value is 25.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 122.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Jun 2025) to 122.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 25.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 92.00 Cr.. The value appears to be declining and may need further review. It has decreased from 93.00 Cr. (Jun 2025) to 92.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 9.06. The value appears to be declining and may need further review. It has decreased from 9.19 (Jun 2025) to 9.06, marking a decrease of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:49 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 322 | 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,669 | 1,712 |
| Expenses | 246 | 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,014 | 1,214 | 1,258 |
| Operating Profit | 76 | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 361 | 455 | 454 |
| OPM % | 24% | 22% | 21% | 21% | 23% | 22% | 24% | 28% | 23% | 24% | 26% | 27% | 27% |
| Other Income | 11 | 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 94 | 128 |
| Interest | 9 | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 14 | 11 |
| Depreciation | 14 | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 63 | 83 | 91 |
| Profit before tax | 63 | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 453 | 481 |
| Tax % | 30% | 27% | 27% | 27% | 27% | 35% | 24% | 25% | 25% | 25% | 25% | 25% | |
| Net Profit | 45 | 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 362 |
| EPS in Rs | 5.11 | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 | 26.91 | 33.41 | 35.72 |
| Dividend Payout % | 20% | 18% | 27% | 40% | 25% | 27% | 18% | 18% | 16% | 16% | 11% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.78% | -22.58% | 14.58% | 29.09% | -8.45% | 47.69% | 41.67% | 8.09% | 21.77% | 44.13% | 31.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | -60.36% | 37.16% | 14.51% | -37.54% | 56.14% | -6.03% | -33.58% | 13.68% | 22.37% | -12.74% |
Poly Medicure Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 19% |
| 3 Years: | 22% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 29% |
| 3 Years: | 34% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 35% |
| 3 Years: | 33% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 12:20 pm
Balance Sheet
Last Updated: December 4, 2025, 1:48 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 | 51 |
| Reserves | 124 | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 | 2,868 |
| Borrowings | 67 | 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 180 | 240 |
| Other Liabilities | 73 | 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 215 | 246 | 429 |
| Total Liabilities | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,587 |
| Fixed Assets | 123 | 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | 1,439 |
| CWIP | 20 | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 | 83 |
| Investments | 3 | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,077 | 930 |
| Other Assets | 140 | 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 748 | 930 | 1,135 |
| Total Assets | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,587 |
Below is a detailed analysis of the balance sheet data for Poly Medicure Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 51.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,868.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,715.00 Cr. (Mar 2025) to 2,868.00 Cr., marking an increase of 153.00 Cr..
- For Borrowings, as of Sep 2025, the value is 240.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 180.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 60.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 429.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 246.00 Cr. (Mar 2025) to 429.00 Cr., marking an increase of 183.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,587.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,192.00 Cr. (Mar 2025) to 3,587.00 Cr., marking an increase of 395.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,439.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,084.00 Cr. (Mar 2025) to 1,439.00 Cr., marking an increase of 355.00 Cr..
- For CWIP, as of Sep 2025, the value is 83.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2025) to 83.00 Cr., marking a decrease of 18.00 Cr..
- For Investments, as of Sep 2025, the value is 930.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,077.00 Cr. (Mar 2025) to 930.00 Cr., marking a decrease of 147.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 930.00 Cr. (Mar 2025) to 1,135.00 Cr., marking an increase of 205.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,587.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,192.00 Cr. (Mar 2025) to 3,587.00 Cr., marking an increase of 395.00 Cr..
Notably, the Reserves (2,868.00 Cr.) exceed the Borrowings (240.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 9.00 | 7.00 | 6.00 | -8.00 | -11.00 | -30.00 | -41.00 | 79.00 | 88.00 | 118.00 | 187.00 | 275.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 59 | 74 | 77 | 79 | 77 | 68 | 72 | 82 | 77 | 72 | 76 |
| Inventory Days | 142 | 148 | 114 | 194 | 161 | 186 | 241 | 217 | 218 | 237 | 205 | 233 |
| Days Payable | 101 | 101 | 76 | 131 | 96 | 123 | 142 | 111 | 115 | 105 | 89 | 71 |
| Cash Conversion Cycle | 94 | 106 | 111 | 140 | 144 | 139 | 166 | 179 | 185 | 209 | 188 | 239 |
| Working Capital Days | 20 | 25 | 35 | 55 | 71 | 56 | 44 | 74 | 81 | 69 | 54 | 74 |
| ROCE % | 33% | 30% | 26% | 24% | 26% | 22% | 25% | 22% | 17% | 18% | 24% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 3,390,349 | 2.18 | 657.42 | 3,300,349 | 2025-12-15 02:38:24 | 2.73% |
| UTI Flexi Cap Fund | 1,381,500 | 1.05 | 267.89 | 2,144,773 | 2025-12-08 04:07:55 | -35.59% |
| SBI Healthcare Opportunities Fund | 600,000 | 2.82 | 116.35 | N/A | N/A | N/A |
| SBI MNC Fund | 500,000 | 1.62 | 96.96 | N/A | N/A | N/A |
| Invesco India ELSS Tax Saver Fund | 356,195 | 2.43 | 69.07 | 330,000 | 2025-12-15 02:38:25 | 7.94% |
| WhiteOak Capital Flexi Cap Fund | 331,163 | 0.94 | 64.22 | 314,311 | 2025-12-15 02:14:18 | 5.36% |
| Quant Multi Cap Fund | 264,798 | 0.58 | 51.35 | N/A | N/A | N/A |
| Invesco India Largecap Fund | 173,600 | 1.95 | 33.66 | 164,003 | 2025-12-15 02:38:25 | 5.85% |
| WhiteOak Capital Mid Cap Fund | 155,414 | 0.69 | 30.14 | 51,906 | 2025-12-08 04:07:55 | 199.41% |
| Invesco India ESG Integration Strategy Fund | 69,721 | 3 | 13.52 | 68,601 | 2025-12-15 02:38:25 | 1.63% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 34.13 | 26.92 | 18.69 | 15.28 | 15.25 |
| Diluted EPS (Rs.) | 34.11 | 26.90 | 18.67 | 15.27 | 15.24 |
| Cash EPS (Rs.) | 41.06 | 33.31 | 24.44 | 20.65 | 18.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 272.95 | 153.18 | 129.41 | 113.40 | 100.71 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 272.95 | 153.18 | 129.41 | 113.40 | 100.71 |
| Revenue From Operations / Share (Rs.) | 164.80 | 143.35 | 116.24 | 96.25 | 82.03 |
| PBDIT / Share (Rs.) | 53.49 | 43.45 | 31.43 | 26.17 | 24.28 |
| PBIT / Share (Rs.) | 45.33 | 36.79 | 25.47 | 20.55 | 19.32 |
| PBT / Share (Rs.) | 44.15 | 35.61 | 24.55 | 20.10 | 18.43 |
| Net Profit / Share (Rs.) | 32.90 | 26.65 | 18.48 | 15.02 | 13.83 |
| NP After MI And SOA / Share (Rs.) | 33.41 | 26.91 | 18.69 | 15.28 | 14.17 |
| PBDIT Margin (%) | 32.45 | 30.30 | 27.04 | 27.19 | 29.59 |
| PBIT Margin (%) | 27.50 | 25.66 | 21.91 | 21.34 | 23.55 |
| PBT Margin (%) | 26.78 | 24.83 | 21.12 | 20.88 | 22.47 |
| Net Profit Margin (%) | 19.96 | 18.58 | 15.90 | 15.60 | 16.85 |
| NP After MI And SOA Margin (%) | 20.27 | 18.77 | 16.07 | 15.87 | 17.27 |
| Return on Networth / Equity (%) | 12.24 | 17.56 | 14.43 | 13.47 | 14.07 |
| Return on Capital Employeed (%) | 16.27 | 23.42 | 19.03 | 17.13 | 17.60 |
| Return On Assets (%) | 10.60 | 13.89 | 11.36 | 10.64 | 11.10 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.03 | 0.06 |
| Total Debt / Equity (X) | 0.06 | 0.11 | 0.11 | 0.11 | 0.10 |
| Asset Turnover Ratio (%) | 0.66 | 0.80 | 0.73 | 0.68 | 0.76 |
| Current Ratio (X) | 5.18 | 2.40 | 2.75 | 3.46 | 4.12 |
| Quick Ratio (X) | 4.41 | 1.77 | 2.04 | 2.71 | 3.38 |
| Inventory Turnover Ratio (X) | 6.59 | 2.16 | 2.25 | 2.39 | 2.22 |
| Dividend Payout Ratio (NP) (%) | 8.97 | 11.14 | 13.37 | 16.36 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 7.21 | 8.93 | 10.14 | 11.95 | 0.00 |
| Earning Retention Ratio (%) | 91.03 | 88.86 | 86.63 | 83.64 | 0.00 |
| Cash Earning Retention Ratio (%) | 92.79 | 91.07 | 89.86 | 88.05 | 0.00 |
| Interest Coverage Ratio (X) | 45.18 | 36.90 | 34.12 | 58.99 | 27.35 |
| Interest Coverage Ratio (Post Tax) (X) | 28.79 | 23.63 | 21.07 | 34.86 | 16.57 |
| Enterprise Value (Cr.) | 22744.56 | 15271.32 | 9107.85 | 9208.87 | 7911.73 |
| EV / Net Operating Revenue (X) | 13.62 | 11.10 | 8.17 | 9.98 | 10.06 |
| EV / EBITDA (X) | 41.97 | 36.62 | 30.20 | 36.69 | 33.99 |
| MarketCap / Net Operating Revenue (X) | 13.61 | 11.08 | 8.20 | 9.86 | 9.97 |
| Retention Ratios (%) | 91.02 | 88.85 | 86.62 | 83.63 | 0.00 |
| Price / BV (X) | 8.21 | 10.37 | 7.36 | 8.37 | 8.12 |
| Price / Net Operating Revenue (X) | 13.61 | 11.08 | 8.20 | 9.86 | 9.97 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Poly Medicure Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 34.13. This value is within the healthy range. It has increased from 26.92 (Mar 24) to 34.13, marking an increase of 7.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 34.11. This value is within the healthy range. It has increased from 26.90 (Mar 24) to 34.11, marking an increase of 7.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 33.31 (Mar 24) to 41.06, marking an increase of 7.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.80. It has increased from 143.35 (Mar 24) to 164.80, marking an increase of 21.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.49. This value is within the healthy range. It has increased from 43.45 (Mar 24) to 53.49, marking an increase of 10.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 45.33. This value is within the healthy range. It has increased from 36.79 (Mar 24) to 45.33, marking an increase of 8.54.
- For PBT / Share (Rs.), as of Mar 25, the value is 44.15. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 44.15, marking an increase of 8.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 32.90. This value is within the healthy range. It has increased from 26.65 (Mar 24) to 32.90, marking an increase of 6.25.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 26.91 (Mar 24) to 33.41, marking an increase of 6.50.
- For PBDIT Margin (%), as of Mar 25, the value is 32.45. This value is within the healthy range. It has increased from 30.30 (Mar 24) to 32.45, marking an increase of 2.15.
- For PBIT Margin (%), as of Mar 25, the value is 27.50. This value exceeds the healthy maximum of 20. It has increased from 25.66 (Mar 24) to 27.50, marking an increase of 1.84.
- For PBT Margin (%), as of Mar 25, the value is 26.78. This value is within the healthy range. It has increased from 24.83 (Mar 24) to 26.78, marking an increase of 1.95.
- For Net Profit Margin (%), as of Mar 25, the value is 19.96. This value exceeds the healthy maximum of 10. It has increased from 18.58 (Mar 24) to 19.96, marking an increase of 1.38.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.27. This value exceeds the healthy maximum of 20. It has increased from 18.77 (Mar 24) to 20.27, marking an increase of 1.50.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.24. This value is below the healthy minimum of 15. It has decreased from 17.56 (Mar 24) to 12.24, marking a decrease of 5.32.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.27. This value is within the healthy range. It has decreased from 23.42 (Mar 24) to 16.27, marking a decrease of 7.15.
- For Return On Assets (%), as of Mar 25, the value is 10.60. This value is within the healthy range. It has decreased from 13.89 (Mar 24) to 10.60, marking a decrease of 3.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.11 (Mar 24) to 0.06, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.66. It has decreased from 0.80 (Mar 24) to 0.66, marking a decrease of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 5.18. This value exceeds the healthy maximum of 3. It has increased from 2.40 (Mar 24) to 5.18, marking an increase of 2.78.
- For Quick Ratio (X), as of Mar 25, the value is 4.41. This value exceeds the healthy maximum of 2. It has increased from 1.77 (Mar 24) to 4.41, marking an increase of 2.64.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.59. This value is within the healthy range. It has increased from 2.16 (Mar 24) to 6.59, marking an increase of 4.43.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 8.97. This value is below the healthy minimum of 20. It has decreased from 11.14 (Mar 24) to 8.97, marking a decrease of 2.17.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 7.21. This value is below the healthy minimum of 20. It has decreased from 8.93 (Mar 24) to 7.21, marking a decrease of 1.72.
- For Earning Retention Ratio (%), as of Mar 25, the value is 91.03. This value exceeds the healthy maximum of 70. It has increased from 88.86 (Mar 24) to 91.03, marking an increase of 2.17.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 92.79. This value exceeds the healthy maximum of 70. It has increased from 91.07 (Mar 24) to 92.79, marking an increase of 1.72.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 45.18. This value is within the healthy range. It has increased from 36.90 (Mar 24) to 45.18, marking an increase of 8.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 28.79. This value is within the healthy range. It has increased from 23.63 (Mar 24) to 28.79, marking an increase of 5.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22,744.56. It has increased from 15,271.32 (Mar 24) to 22,744.56, marking an increase of 7,473.24.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 3. It has increased from 11.10 (Mar 24) to 13.62, marking an increase of 2.52.
- For EV / EBITDA (X), as of Mar 25, the value is 41.97. This value exceeds the healthy maximum of 15. It has increased from 36.62 (Mar 24) to 41.97, marking an increase of 5.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
- For Retention Ratios (%), as of Mar 25, the value is 91.02. This value exceeds the healthy maximum of 70. It has increased from 88.85 (Mar 24) to 91.02, marking an increase of 2.17.
- For Price / BV (X), as of Mar 25, the value is 8.21. This value exceeds the healthy maximum of 3. It has decreased from 10.37 (Mar 24) to 8.21, marking a decrease of 2.16.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Poly Medicure Ltd:
- Net Profit Margin: 19.96%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.27% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.24% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 28.79
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 49.4 (Industry average Stock P/E: 24.05)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.96%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | No. 232-B, 3rd Floor, New Delhi Delhi 110020 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Devendra Raj Mehta | Chairman (Non - Executive) & Non Independent Direc |
| Mr. Himanshu Baid | Managing Director |
| Mr. Rishi Baid | Joint Managing Director |
| Mr. Vishal Baid | Executive Director |
| Mr. Jugal Kishore Baid | Non Exe.Non Ind.Director |
| Mr. Alessandro Balboni | Non Exe.Non Ind.Director |
| Dr. Ambrish Mithal | Ind. Non-Executive Director |
| Mr. Vimal Bhandari | Ind. Non-Executive Director |
| Mr. Amit Khosla | Ind. Non-Executive Director |
| Ms. Sonal Mattoo | Ind. Non-Executive Director |
| Mr. Vishal Gupta | Ind. Non-Executive Director |
| Mr. Pankaj Kumar Gupta | Additional Executive Director |
FAQ
What is the intrinsic value of Poly Medicure Ltd?
Poly Medicure Ltd's intrinsic value (as of 07 January 2026) is ₹1801.91 which is 2.21% higher the current market price of ₹1,763.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹17,869 Cr. market cap, FY2025-2026 high/low of ₹2,938/1,683, reserves of ₹2,868 Cr, and liabilities of ₹3,587 Cr.
What is the Market Cap of Poly Medicure Ltd?
The Market Cap of Poly Medicure Ltd is 17,869 Cr..
What is the current Stock Price of Poly Medicure Ltd as on 07 January 2026?
The current stock price of Poly Medicure Ltd as on 07 January 2026 is ₹1,763.
What is the High / Low of Poly Medicure Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Poly Medicure Ltd stocks is ₹2,938/1,683.
What is the Stock P/E of Poly Medicure Ltd?
The Stock P/E of Poly Medicure Ltd is 49.4.
What is the Book Value of Poly Medicure Ltd?
The Book Value of Poly Medicure Ltd is 288.
What is the Dividend Yield of Poly Medicure Ltd?
The Dividend Yield of Poly Medicure Ltd is 0.20 %.
What is the ROCE of Poly Medicure Ltd?
The ROCE of Poly Medicure Ltd is 20.1 %.
What is the ROE of Poly Medicure Ltd?
The ROE of Poly Medicure Ltd is 15.8 %.
What is the Face Value of Poly Medicure Ltd?
The Face Value of Poly Medicure Ltd is 5.00.